SCHEMBL16985200

SCHEMBL16985200

CCNc1cc(OC)ccc1C

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.56
TSHR P16473 1/20 0.56
RECQL P46063 1/20 0.56
MAPT P10636 5/20 0.44
LMNA P02545 4/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
DHFR P00374 1/20 0.43
P2RX7 Q99572 1/20 0.43
GAA P10253 6/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
MAPK1 P28482 1/20 0.41
ALDH1A1 P00352 3/20 0.41
BCHE P06276 1/20 0.40
ACHE P22303 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
USP2 O75604 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16301339 0.85 TDP1 (0.44) CYP3A4TSHRRECQLMAPTLMNA
SCHEMBL20512947 0.85 GAA (0.54) CYP3A4TSHRRECQLMAPTLMNA
Hydrochloric Acid SCHEMBL14999773 0.83 GAA (0.53) CYP3A4TSHRRECQLMAPTLMNA
SCHEMBL2498219 0.81 KMT2A (0.54) TSHRMAPTLMNAL3MBTL1GAA
SCHEMBL31377084 0.81 KMT2A (0.54) TSHRMAPTLMNAL3MBTL1GAA
SCHEMBL31377083 0.81 KMT2A (0.54) TSHRMAPTLMNAL3MBTL1GAA
SCHEMBL11820720 0.79 GAA (0.50) CYP3A4TSHRRECQLMAPTLMNA
SCHEMBL21635515 0.79 TDP1 (0.60) MAPTLMNAP2RX7GAAMEN1
SCHEMBL2823284 0.79 GAA (0.47) MAPTLMNANPC1RAB9AP2RX7
SCHEMBL19072872 0.79 ALDH1A1 (0.40) TSHRMAPTLMNAL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219499-A1 A CLASS OF FUSED RING COMPOUNDS, AND PREPARATION AND USE THEREOF CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) 2023-08-02 EP disclosed
WO-2022006439-A2 COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2022-01-06 WO disclosed
US-20170145214-A1 FLUOROGENIC PH-SENSITIVE DYES AND THEIR METHODS OF USE (II) Life Technologies Corporation 2017-05-25 US disclosed
US-9599622-B2 Fluorogenic pH-sensitive dyes and their methods of use (II) Life Technologies Corporation (US) 2017-03-21 US disclosed
US-20150241438-A1 Fluorogenic pH-Sensitive Dyes and Their Methods of Use Life Technologies Corporation 2015-08-27 US disclosed
US-20150218379-A1 Fluorogenic pH-Sensitive Dyes and Their Methods of Use (II) Life Technologies Corporation 2015-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150241438-A1 Fluorogenic pH-Sensitive Dyes and Their Methods of Use ALPG, XDH, HEXD CYP3A4 1155/4885TSHR 4478/4885RECQL 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.